<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03952325</url>
  </required_header>
  <id_info>
    <org_study_id>ODO-TE-B202</org_study_id>
    <nct_id>NCT03952325</nct_id>
  </id_info>
  <brief_title>Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC</brief_title>
  <acronym>CONTESSA TRIO</acronym>
  <official_title>A Multicenter, Phase 2 Study of Tesetaxel Plus Three Different PD-(L)1 Inhibitors in Patients With Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly and Non-Elderly Adult Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odonate Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odonate Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CONTESSA TRIO is a multi-cohort, multicenter, Phase 2 study of tesetaxel, an investigational,&#xD;
      orally administered taxane, in patients with metastatic breast cancer (MBC). In Cohort 1,&#xD;
      approximately 200 patients with triple-negative MBC who have not received prior chemotherapy&#xD;
      for advanced disease will be randomized 1:1:1 to receive tesetaxel plus either: (1)&#xD;
      nivolumab; (2) pembrolizumab; or (3) atezolizumab. The primary efficacy endpoints for Cohort&#xD;
      1 are objective response rate (ORR) and progression free survival (PFS) in patients with&#xD;
      programmed death-ligand 1 (PD-L1) positive status. In Cohort 2, approximately 60 elderly&#xD;
      patients with human epidermal growth factor receptor 2 (HER2) negative MBC who have not&#xD;
      received prior chemotherapy for advanced disease will receive tesetaxel monotherapy. The&#xD;
      primary efficacy endpoints for Cohort 2 are ORR and PFS in patients with hormone receptor&#xD;
      (HR)-positive, HER2-negative disease. In Cohort 3, approximately 60 non-elderly adult&#xD;
      patients with HER2-negative MBC who have not received prior chemotherapy for advanced disease&#xD;
      will receive tesetaxel monotherapy. The primary efficacy endpoints for Cohort 3 are ORR and&#xD;
      PFS in patients with HR positive, HER2-negative disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CONTESSA TRIO is a multi-cohort, multicenter, Phase 2 study of tesetaxel, an investigational,&#xD;
      orally administered taxane, in patients with MBC.&#xD;
&#xD;
      Cohort 1:&#xD;
&#xD;
      Approximately 200 patients with triple-negative MBC who have not received prior chemotherapy&#xD;
      for advanced disease will be randomized 1:1:1 to receive tesetaxel dosed orally at 27 mg/m2&#xD;
      once every three weeks (Q3W) plus either:&#xD;
&#xD;
        -  Nivolumab at 360 mg by intravenous infusion Q3W;&#xD;
&#xD;
        -  Pembrolizumab at 200 mg by intravenous infusion Q3W; or&#xD;
&#xD;
        -  Atezolizumab at 1,200 mg by intravenous infusion Q3W.&#xD;
&#xD;
      Nivolumab and pembrolizumab (programmed cell death protein 1 [PD-1] inhibitors) and&#xD;
      atezolizumab (a programmed death-ligand 1 [PD-L1] inhibitor) are immuno-oncology (IO) agents&#xD;
      approved for the treatment of multiple types of cancer. Two of these agents, atezolizumab and&#xD;
      pembrolizumab, have been approved by the U.S. Food and Drug Administration (FDA) as a&#xD;
      first-line treatment for patients with triple-negative MBC. The primary efficacy endpoints&#xD;
      for Cohort 1 are ORR and PFS in patients with PD-L1 positive status. The secondary efficacy&#xD;
      endpoints are ORR and PFS in all patients, duration of response (DoR) and overall survival&#xD;
      (OS).&#xD;
&#xD;
      Cohort 2:&#xD;
&#xD;
      Approximately 60 elderly patients with HER2-negative MBC who have not received prior&#xD;
      chemotherapy for advanced disease will receive tesetaxel monotherapy dosed orally at 27 mg/m2&#xD;
      Q3W. The primary efficacy endpoints for Cohort 2 are ORR and PFS in patients with&#xD;
      HR-positive, HER2-negative disease. The secondary efficacy endpoints are ORR and PFS in&#xD;
      patients with triple-negative disease, DoR and OS.&#xD;
&#xD;
      Cohort 3:&#xD;
&#xD;
      Approximately 60 non-elderly adult patients with HER2-negative MBC who have not received&#xD;
      prior chemotherapy for advanced disease will receive tesetaxel monotherapy dosed orally at 27&#xD;
      mg/m2 Q3W. The primary efficacy endpoints for Cohort 3 are ORR and PFS in patients with HR&#xD;
      positive, HER2-negative disease. The secondary efficacy endpoints are ORR and PFS in patients&#xD;
      with triple negative disease, DoR and OS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The Sponsor has discontinued the development of tesetaxel&#xD;
  </why_stopped>
  <start_date type="Actual">July 9, 2019</start_date>
  <completion_date type="Actual">June 23, 2021</completion_date>
  <primary_completion_date type="Actual">June 23, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort 1: ORR in patients with PD-L1 positive status</measure>
    <time_frame>Approximately 2.0-3.0 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 1: PFS in patients with PD-L1 positive status</measure>
    <time_frame>Approximately 2.5-3.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2: ORR in patients with HR-positive, HER2-negative disease</measure>
    <time_frame>Approximately 2.0-3.0 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2: PFS in patients with HR-positive, HER2-negative disease</measure>
    <time_frame>Approximately 2.0-3.0 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 3: ORR in patients with HR-positive, HER2-negative disease</measure>
    <time_frame>Approximately 2.0-3.0 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 3: PFS in patients with HR-positive, HER2-negative disease</measure>
    <time_frame>Approximately 2.0-3.0 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: ORR in all patients</measure>
    <time_frame>Approximately 2.0-3.0 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: PFS in all patients</measure>
    <time_frame>Approximately 2.0-3.0 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: DoR</measure>
    <time_frame>Approximately 2.5-3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: OS</measure>
    <time_frame>Approximately 4.0-5.0 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: ORR in patients with triple-negative disease</measure>
    <time_frame>Approximately 2.0-3.0 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: PFS in patients with triple-negative disease</measure>
    <time_frame>Approximately 2.5-3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: DoR</measure>
    <time_frame>Approximately 2.5-3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: OS</measure>
    <time_frame>Approximately 4.0-5.0 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 3: ORR in patients with triple-negative disease</measure>
    <time_frame>Approximately 1.0-2.0 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 3: PFS in patients with triple-negative disease</measure>
    <time_frame>Approximately 1.5-2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 3: DoR</measure>
    <time_frame>Approximately 2.5-3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 3: OS</measure>
    <time_frame>Approximately 4.0-5.0 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Cohort 1: ORR by level of PD-L1 expression as determined by central PD-L1 testing</measure>
    <time_frame>Approximately 2.0-3.0 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 1: PFS by level of PD-L1 expression as determined by central PD-L1 testing</measure>
    <time_frame>Approximately 2.5-3.5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 1: Central nervous system (CNS) ORR in patients with CNS metastases at baseline</measure>
    <time_frame>Approximately 2.0-3.0 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 1: CNS DoR in patients with CNS metastases at baseline</measure>
    <time_frame>Approximately 2.5-3.5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 2: CNS ORR in patients with CNS metastases at baseline</measure>
    <time_frame>Approximately 2.0-3.0 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 2: CNS DoR in patients with CNS metastases at baseline</measure>
    <time_frame>Approximately 2.5-3.5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 3: CNS ORR in patients with CNS metastases at baseline</measure>
    <time_frame>Approximately 1.0-2.0 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 3: CNS DoR in patients with CNS metastases at baseline</measure>
    <time_frame>Approximately 1.5-2.5 years</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">294</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1, Arm A: Tesetaxel plus nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Arm B: Tesetaxel plus pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Arm C: Tesetaxel plus atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Tesetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Tesetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesetaxel</intervention_name>
    <description>Tesetaxel at 27 mg/m2 orally Q3W</description>
    <arm_group_label>Cohort 1, Arm A: Tesetaxel plus nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesetaxel</intervention_name>
    <description>Tesetaxel at 27 mg/m2 orally Q3W</description>
    <arm_group_label>Cohort 1, Arm B: Tesetaxel plus pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesetaxel</intervention_name>
    <description>Tesetaxel at 27 mg/m2 orally Q3W</description>
    <arm_group_label>Cohort 1, Arm C: Tesetaxel plus atezolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab at 360 mg by intravenous infusion Q3W</description>
    <arm_group_label>Cohort 1, Arm A: Tesetaxel plus nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab at 200 mg by intravenous infusion Q3W</description>
    <arm_group_label>Cohort 1, Arm B: Tesetaxel plus pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab at 1,200 mg by intravenous infusion Q3W</description>
    <arm_group_label>Cohort 1, Arm C: Tesetaxel plus atezolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesetaxel</intervention_name>
    <description>Tesetaxel at 27 mg/m2 orally Q3W</description>
    <arm_group_label>Cohort 2: Tesetaxel</arm_group_label>
    <arm_group_label>Cohort 3: Tesetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or male patients aged:&#xD;
&#xD;
               -  Cohort 1: ≥ 18 years old&#xD;
&#xD;
               -  Cohort 2: ≥ 65 years old&#xD;
&#xD;
               -  Cohort 3: ≥ 18 to &lt; 65 years old&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer&#xD;
&#xD;
          -  Most recent biopsy must be HER2-negative&#xD;
&#xD;
          -  Cohort 1 only: Most recent biopsy must be hormone receptor (HR) (estrogen receptor and&#xD;
             progesterone receptor) negative&#xD;
&#xD;
          -  Measurable disease per RECIST 1.1.&#xD;
&#xD;
               -  Patients with bone-only metastatic cancer must have a measurable lytic or mixed&#xD;
                  lytic-blastic lesion&#xD;
&#xD;
               -  Known metastases to the CNS are permitted but not required&#xD;
&#xD;
          -  Documented (including de novo): (a) locally advanced breast cancer that is not&#xD;
             considered curable by surgery and/or radiation; or (b) metastatic breast cancer&#xD;
&#xD;
          -  Disease-free interval of at least 12 months after the completion of systemic&#xD;
             neoadjuvant or adjuvant chemotherapy for patients previously treated with systemic&#xD;
             chemotherapy for a tumor surgically resected with curative intent&#xD;
&#xD;
          -  Cohorts 2 and 3 only: Prior endocrine therapy with or without a cyclin-dependent&#xD;
             kinase (CDK) 4/6 inhibitor unless endocrine therapy is not indicated. Any prior&#xD;
             targeted therapies are permitted. There is no limit to the number of prior endocrine&#xD;
             therapies.&#xD;
&#xD;
          -  Cohort 1 only: At Screening, patients must have documented evidence of positive PD-L1&#xD;
             expression as assessed via immunohistochemistry (IHC) scoring by local, regional, or&#xD;
             central laboratory testing&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2&#xD;
&#xD;
          -  Adequate bone marrow, hepatic and renal function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy for locally advanced or metastatic disease&#xD;
&#xD;
          -  Cohort 1 only: prior treatment with pembrolizumab, nivolumab, atezolizumab, any other&#xD;
             PD-(L)1/PD-L2 inhibitor or a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)&#xD;
             inhibitor&#xD;
&#xD;
          -  Current evidence or history of leptomeningeal disease&#xD;
&#xD;
          -  Known human immunodeficiency virus infection, unless well controlled&#xD;
&#xD;
          -  Known active hepatitis B or known active hepatitis C infection&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with Study participation or&#xD;
             investigational product administration or may interfere with the interpretation of&#xD;
             Study results&#xD;
&#xD;
          -  Presence of neuropathy Grade &gt; 1&#xD;
&#xD;
          -  History of hypersensitivity to any of the Study drugs or any of their ingredients, as&#xD;
             applicable&#xD;
&#xD;
          -  Cohort 1 only:&#xD;
&#xD;
               -  Chronic autoimmune disease&#xD;
&#xD;
               -  Evidence of active, non-infectious pneumonia (eg, pneumonia due to autoimmune or&#xD;
                  connective tissue disease)&#xD;
&#xD;
               -  Treatment with a live vaccine within 30 days prior to the first dose of&#xD;
                  nivolumab, pembrolizumab or atezolizumab&#xD;
&#xD;
               -  History of active tuberculosis&#xD;
&#xD;
               -  Prior organ transplantation including allogeneic stem cell transplantation&#xD;
&#xD;
               -  Active infection requiring systemic therapy&#xD;
&#xD;
               -  Current or prior use of immunosuppressive medication within 7 days prior to Cycle&#xD;
                  1, Day 1&#xD;
&#xD;
               -  Active autoimmune disease that might deteriorate when receiving an&#xD;
                  immunostimulatory agent&#xD;
&#xD;
          -  Anticancer treatment, including endocrine therapy, radiotherapy (except stereotactic&#xD;
             brain radiosurgery), chemotherapy or biologic therapy, ≤ 14 days prior to Enrollment&#xD;
&#xD;
          -  Major surgery ≤ 28 days prior to Enrollment&#xD;
&#xD;
          -  Less than 2 weeks or 5 plasma half-lives (whichever is greater) since last use of a&#xD;
             medication or ingestion of an agent, beverage or food that is a known clinically&#xD;
             relevant strong inhibitor or known clinically relevant inducer of the cytochrome P450&#xD;
             (CYP) 3A pathway&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph O'Connell, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Odonate Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute - Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists and Research Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists and Research Institute - Panhandle Region</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists and Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Cancer and Blood Specialists</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins Singapore International Medical Centre</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tesetaxel</keyword>
  <keyword>PD-(L)1 inhibitor</keyword>
  <keyword>Triple-negative breast cancer</keyword>
  <keyword>Locally advanced or metastatic breast cancer</keyword>
  <keyword>Taxane</keyword>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Combination of tesetaxel and PD-(L)1 inhibitors</keyword>
  <keyword>HER2 negative</keyword>
  <keyword>Oral chemotherapy</keyword>
  <keyword>Central nervous system (CNS) metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

